Results 81 to 90 of about 3,310,810 (118)
Improvements in Clinical Cancer Care Associated with Integration of Personalized Medicine
Background: While adoption of personalized medicine (PM) continues to increase in clinical oncology, there is limited data connecting the level of PM adoption at a given institution to improved clinical outcomes for patients.
Daryl Pritchard +5 more
core +1 more source
Charles Forscher,1 Monica Mita,2 Robert Figlin3 1Sarcoma Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars ...
Forscher C, Mita M, Figlin R
core
NAT10 Promotes ox-LDL-Induced Endothelial Ferroptosis by Stabilizing TFRC mRNA via ac4C Modification
Wenjuan Zhang +2 more
doaj +1 more source
Targeted therapies in epilepsies
In recent years, the increasing availability of antiseizure medications has not reduced the incidence of drug-resistant epilepsy. Precision medicine offers the potential for mechanism-driven treatments for rare pediatric epilepsies. The concept of precision medicine is not new in the field of epilepsy, as demonstrated by the use of pyridoxine for ...
openaire +2 more sources
Recent study and Targeted Therapy of CML
Chronic myeloid leukemia (CML) is a stem cell disease which is typical for increased and unregulated accumulation of predominantly clonal myeloid cells in hematopoietic tissue.
Kwak, Jeongwan
core
Harnessing lentiviral vectors for in vivo gene therapy of liver metastases
Giovanna Giacca +2 more
doaj +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Immunotherapy, 2010
745 ISSN 1750-743X Immunotherapy (2010) 2(6), 745–748 10.2217/IMT.10.66 © 2010 Future Medicine Ltd “Although it would be naive to conclude that biomarker programs are cheap and straightforward, it is likely to be a price worth paying in order to maximize the chance of success in the tortuous process of cancer drug development, and, ultimately, to ...
William, Shingler, Richard, Harrop
openaire +2 more sources
745 ISSN 1750-743X Immunotherapy (2010) 2(6), 745–748 10.2217/IMT.10.66 © 2010 Future Medicine Ltd “Although it would be naive to conclude that biomarker programs are cheap and straightforward, it is likely to be a price worth paying in order to maximize the chance of success in the tortuous process of cancer drug development, and, ultimately, to ...
William, Shingler, Richard, Harrop
openaire +2 more sources

